Bristol-Myers Squibb (BMS) has reported positive results from a Phase II clinical trial of BMS-986036 to treat non-alcoholic steatohepatitis (NASH) patients.

BMS-986036 is an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results from the randomised, multi-centre, double-blind, placebo-controlled, parallel group, multiple-dose Phase II trial showed that the product has met the primary endpoint of significant reduction in liver fat compared to placebo.

The trial assessed the safety, pharmacodynamics and pharmacokinetic effects of the product in 74 adults with biopsy-confirmed NASH.

Bristol-Myers Squibb cardiovascular, fibrosis and immunoscience development head Mike Burgess said: “We are encouraged by the improvements these data showed across multiple aspects of NASH, and that patients could be effectively evaluated through imaging rather than through invasive liver biopsy.

See Also:

"This data, along with previously announced Phase II data in patients with type 2 diabetes, supports further clinical research of BMS-986036 as a potential treatment for NASH."

“This data, along with previously announced Phase II data in patients with type 2 diabetes, supports further clinical research of BMS-986036 as a potential treatment for NASH."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial evaluated subcutaneous injections of BMS-986036 at 10mg per day over a period of 16 weeks.

The primary endpoint of the trial was total change in MRI-PDFF at week 16, while the exploratory endpoints included measure of serum Pro-C3, enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and liver stiffness.

It was observed that there was statistically significant improvement in the prespecified exploratory endpoints and the safety profile was also found to be encouraging.

Ambrx licenced the exclusive research, development and commercialisation rights of BMS-986036 to BMS.